Grandbrothers/iStock Editorial via Getty Images
The FDA said it is evaluating the need for additional regulatory action regarding the safety of bluebird bio’s (NASDAQ:BLUE) gene therapy Skysona, which is used to treat children with cerebral adrenoleukodystrophy.
The agency said in a statement Wednesday that it